Cost-effectiveness of ruxolitinib vs. Best Available Therapy in the treatment of myelofibrosis in Spain

Authors: Gómez-Casares MT, Hernández-Boluda JC, Jiménez-Velasco A, Martínez-López J, Ferrario MG, Gozalbo Irmina, Gostkorzewicz J, Subirá R


Download PDF